New hope for hard-to-treat colorectal cancer: targeted drug enters human trials
NCT ID NCT07535112
First seen Apr 25, 2026 · Last updated May 20, 2026 · Updated 3 times
Summary
This study tests a new drug, BAY 3771249, for people with advanced colorectal cancer that has a specific change in the KRAS gene (G12D). The drug aims to block the faulty protein and slow or stop cancer growth. About 130 adults will receive the drug alone or with another drug called cetuximab. The goal is to find a safe dose and see if it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC COLORECTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Border Medical oncology - Albury Wodonga Regional Cancer Centre
NOT_YET_RECRUITINGAlbury, New South Wales, 2640, Australia
-
Cabrini Health Oncology Research
NOT_YET_RECRUITINGMalvern, Victoria, 3144, Australia
-
Calvary Mater Hospital Newcastle - Oncology
RECRUITINGWaratah, New South Wales, 2298, Australia
-
City of Hope - Duarte Cancer Center
NOT_YET_RECRUITINGDuarte, California, 91010, United States
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
NOT_YET_RECRUITINGRoma, 00128, Italy
-
Ghent University Hospital | Drug Research Unit Department
NOT_YET_RECRUITINGGhent, 9000, Belgium
-
HUS-Yhtymä, Helsingin yliopistollinen sairaala (HUS) - Syöpäkeskus
NOT_YET_RECRUITINGHelsinki, Uusimaa, 00029, Finland
-
Hospital Universitari Vall D Hebron | Oncologia
NOT_YET_RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario Hm Sanchinarro | Oncologia
NOT_YET_RECRUITINGMadrid, 28050, Spain
-
Icahn School of Medicine at Mount Sinai - Oncology
NOT_YET_RECRUITINGNew York, New York, 10029, United States
-
Karolinska Universitetssjukhuset - Fas I-enheten Solna CKC
NOT_YET_RECRUITINGStockholm, Stockholm County, 171 76, Sweden
-
Mayo Clinic - Cancer Center - Phoenix
NOT_YET_RECRUITINGPhoenix, Arizona, 85054, United States
-
NEXT Dallas - Oncology Department
RECRUITINGIrving, Texas, 75039, United States
-
National Cancer Center Singapore - Oncology Department
RECRUITINGSingapore, 168583, Singapore
-
National University Hospital Medical Centre
NOT_YET_RECRUITINGSingapore, 119074, Singapore
-
Nederlands Kanker Instituut
NOT_YET_RECRUITINGAmsterdam, North Holland, 1066 CX, Netherlands
-
Odense University Hospital - Oncology Department
NOT_YET_RECRUITINGOdense, Region Syddanmark, 5000, Denmark
-
Rigshospitalet - Kræftbehandling
NOT_YET_RECRUITINGCopenhagen, Capital Region, 2100, Denmark
-
START | San Antonio
NOT_YET_RECRUITINGSan Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
NOT_YET_RECRUITINGDenver, Colorado, 80218, United States
-
UC San Diego Health - Moores Cancer Center
NOT_YET_RECRUITINGSan Diego, California, 92037, United States
Conditions
Explore the condition pages connected to this study.